Research graph
References from Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death. Local targets link to admitted publications; unresolved targets remain external evidence.
Differential activation of adipogenesis by multiple PPAR isoforms
10.1101/gad.10.8.974 · 1996 · External reference
Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
1997 · External reference
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
10.1073/pnas.91.15.7355 · 1994 · External reference
PPARg agonists inhibit production of monocyte inflammatory cytokines
10.1038/35154 · 1998 · External reference
Peroxisome proliferator-activated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs
10.1074/jbc.272.6.3406 · 1997 · External reference
15-deoxy-12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-gamma
10.1016/0092-8674(95)90193-0 · 1995 · External reference
PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL
10.1016/s0092-8674(00)81575-5 · 1998 · External reference
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor g and the retinoid X receptor
10.1073/pnas.94.1.237 · 1997 · External reference
Terminal differentiation of human breast cancer through PPARg
10.1016/s1097-2765(00)80047-7 · 1998 · External reference
Ligands for peroxisome proliferator-activated receptor g and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer in vitro and in BNX mice
10.1073/pnas.95.15.8806 · 1998 · External reference
The nuclear eicosanoid receptor, PPARg, is aberrantly expressed in colonic cancers
10.1093/carcin/19.1.49 · 1998 · External reference
Activation of PPARg leads to inhibition of anchorage-independent growth of human colorectal cancer cells
10.1016/s0016-5085(98)70072-1 · 1998 · External reference
Differential expression of the peroxisome proliferatoractivated receptor g (PPARg) and its coactivators steroid receptor coactivator-1 PPAR-binding protein PBP in the brown fat, urinary bladder, colon, breast of the mouse
10.1016/s0002-9440(10)65577-0 · 1998 · External reference
PGE2, PGF2a, 6-keto-PGE1a, TxB2 synthesis along the rabbit nephron
1987 · External reference
Occurrence of 9-deoxy-D9,12-dihydroprostaglandin D2 in human urine
10.1016/s0021-9258(18)37435-0 · 1988 · External reference
Eicosanoid synthesis by cultured human urothelial cells: potential role in bladder cancer
1986 · External reference
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
10.1172/jci118991 · 1996 · External reference
Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas
1996 · External reference
Convergence of 9-cis-RA and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
10.1038/358771a0 · 1992 · External reference
Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor g (PPARg) heterodimers: intermolecular synergy requires only the PPARg hormone-dependent activation function
10.1128/mcb.18.6.3483 · 1998 · External reference
Differentiation and reversal of malignant changes in colon cancer through PPARgamma [see comments]
10.1038/2030 · 1998 · External reference
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors g1 and g2
10.1006/bbrc.1996.1044 · 1996 · External reference
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
10.1016/0092-8674(95)90194-9 · 1995 · External reference
Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients
10.3109/07853899808999405 · 1998 · External reference
Ligand for peroxisome proliferator-activated receptor g (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
1998 · External reference
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
10.1038/386407a0 · 1997 · External reference
Retinoids in bladder, testis, prostate cancer: epidemiologic, preclinical and clinical observations
1994 · External reference
13-cis-RA: inhibition of bladder carcinogenesis in the rat
10.1126/science.835006 · 1977 · External reference
Megadose vitamins in bladder cancer: a double blind clinical trial
10.1016/s0022-5347(17)34863-2 · 1994 · External reference
Prevention of breast cancer in the rat with 9-cis-RA as a single agent and in combination with tamoxifen
1994 · External reference
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand
1996 · External reference
Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlated in non-invasive and invasive bladder transitional cell carcinomas
1998 · External reference
Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty-acid binding protein [PA-FABP]) that is highly up-regulated in psoriasis skin and that shares similarity to fatty-acid binding proteins
10.1111/1523-1747.ep12616641 · 1992 · External reference
Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor
1995 · External reference
Members of the fatty acid binding protein family are differentiation factors for the mammary gland
10.1083/jcb.127.4.1097 · 1994 · External reference
